Phase 2 trial of Brimochol to treat presbyopia underway
The first patients have been dosed in a phase 2 clinical trial investigating Brimochol for the treatment of presbyopia, according to a press release from Visus Therapeutics.
The double-masked, randomized crossover trial is investigating the safety and efficacy of two formulations of Brimochol topical ophthalmic solution (carbachol and brimonidine tartrate) in patients with emmetropic phakic and pseudophakic presbyopia, the release said. About 42 patients will be enrolled in the 30-day trial.
“By combining the unique properties of carbachol and brimonidine tartrate into one novel eye drop, Brimochol has the potential to be a meaningful advancement for the category,” Rhett Schiffman, MD, MS, MHSA, co-founder, chief medical officer and head of research and development at Visus Therapeutics, said in the release.
The primary endpoint of the trial is the percentage of patients who gain three lines or more in near visual acuity without losing distance vision, the release said.
Visus expects topline data to be available midyear.
Read more about